Spots Global Cancer Trial Database for rucaparib
Every month we try and update this database with for rucaparib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors | NCT03911453 | Breast Cancer | Rucaparib | 21 Years - | University of Arizona | |
| A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | NCT02042378 | Pancreatic Canc... Pancreatic Duct... | Rucaparib | 18 Years - | pharmaand GmbH | |
| Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination | NCT03462212 | Advanced (Stage... | Carboplatin Paclitaxel Bevacizumab Rucaparib | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients | NCT04227522 | Ovarian Cancer Fallopian Tube ... Primary Periton... Clear Cell Carc... | Rucaparib Placebos | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer | NCT04253262 | Metastatic Cast... | Rucaparib Copanlisib | 18 Years - | Brown University | |
| The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) | NCT03694262 | Endometrial Can... Uterine Carcino... | Rucaparib Bevacizumab Atezolizumab | 18 Years - | Medical College of Wisconsin | |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | NCT02975934 | Metastatic Cast... | Rucaparib Abiraterone ace... | 18 Years - | pharmaand GmbH | |
| Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives | NCT03954366 | Neoplasms | Rucaparib Rosuvastatin Oral Contracept... | 18 Years - | pharmaand GmbH | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy | NCT03140670 | Pancreatic Canc... | RUCAPARIB | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer | NCT03101280 | Gynecologic Neo... | Atezolizumab Rucaparib | 18 Years - | Hoffmann-La Roche | |
| Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) | NCT01968213 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Rucaparib Placebo | 18 Years - | pharmaand GmbH | |
| Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer | NCT03559049 | Stage IV Non-sm... | Pembrolizumab Pemetrexed Carboplatin Rucaparib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Rucaparib Maintenance Therapy in Advanced Cervical Cancer | NCT03795272 | Cervical Cancer | Rucaparib Placebo | 18 Years - 100 Years | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | |
| Rucaparib in Nonmetastatic prOstAte With BRCAness | NCT03533946 | Prostate Cancer | Rucaparib | 18 Years - | University of Utah | |
| A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer | NCT04253262 | Metastatic Cast... | Rucaparib Copanlisib | 18 Years - | Brown University | |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | NCT03397394 | Bladder Cancer Urothelial Carc... Metastatic Urot... Renal Pelvis Ca... Ureter Carcinom... Urinary Bladder... Urethra Carcino... Muscle Invasive... | Rucaparib | 18 Years - | pharmaand GmbH | |
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib | NCT04676334 | Metastatic Cast... Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... Other Solid Tum... | Rucaparib | 18 Years - | pharmaand GmbH | |
| Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy | NCT03140670 | Pancreatic Canc... | RUCAPARIB | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor | NCT03499444 | Advanced Solid ... | Rucaparib | 20 Years - | pharmaand GmbH | |
| Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency | NCT03442556 | ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... Castration Leve... Castration-Resi... Homologous Reco... Prostate Carcin... PSA Level Great... PSA Progression Stage IV Prosta... | Carboplatin Docetaxel Laboratory Biom... Rucaparib Camsy... Rucaparib | 18 Years - | University of Washington | |
| A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. | NCT03840200 | Breast Cancer Prostate Cancer Ovarian Cancer | Ipatasertib Rucaparib | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | NCT03824704 | Epithelial Ovar... Fallopian Tube ... Primary Periton... High Grade Sero... Endometrioid Ad... | Rucaparib Nivolumab | 18 Years - | pharmaand GmbH | |
| Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer | NCT03559049 | Stage IV Non-sm... | Pembrolizumab Pemetrexed Carboplatin Rucaparib | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | NCT01891344 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Oral rucaparib | 18 Years - | pharmaand GmbH | |
| Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors | NCT04276376 | Solid Tumor | Atezolizumab Rucaparib | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients | NCT04227522 | Ovarian Cancer Fallopian Tube ... Primary Periton... Clear Cell Carc... | Rucaparib Placebos | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months | NCT04826198 | Ovarian Cancer | AsiDNA Niraparib Olaparib Rucaparib | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib | NCT02986100 | Solid Tumor | C-14 labeled Ru... Rucaparib | 18 Years - | pharmaand GmbH | |
| A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy | NCT03542175 | Breast Cancer | Rucaparib Radiotherapy | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study | NCT04539327 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | Rucaparib | 18 Years - | Grupo Español de Investigación en Cáncer de Ovario | |
| Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma | NCT03958045 | Small Cell Lung... | Rucaparib and N... | 18 Years - | University of Kentucky | |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | NCT02975934 | Metastatic Cast... | Rucaparib Abiraterone ace... | 18 Years - | pharmaand GmbH | |
| Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives | NCT03954366 | Neoplasms | Rucaparib Rosuvastatin Oral Contracept... | 18 Years - | pharmaand GmbH | |
| The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) | NCT03694262 | Endometrial Can... Uterine Carcino... | Rucaparib Bevacizumab Atezolizumab | 18 Years - | Medical College of Wisconsin | |
| A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes | NCT04171700 | Solid Tumor | Rucaparib | 18 Years - | pharmaand GmbH | |
| A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | NCT01482715 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Advanced Solid ... | Rucaparib | 18 Years - | pharmaand GmbH | |
| A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | NCT03992131 | Ovarian Cancer Triple-negative... Urothelial Carc... Solid Tumor | Rucaparib Lucitanib Sacituzumab gov... | 18 Years - | pharmaand GmbH | |
| Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients | NCT04227522 | Ovarian Cancer Fallopian Tube ... Primary Periton... Clear Cell Carc... | Rucaparib Placebos | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor | NCT03499444 | Advanced Solid ... | Rucaparib | 20 Years - | pharmaand GmbH | |
| Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma | NCT03995017 | Esophagus Cance... Stomach Cancer,... | Rucaparib Ramucirumab Nivolumab | 18 Years - | University of Kansas Medical Center | |
| A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer | NCT03101280 | Gynecologic Neo... | Atezolizumab Rucaparib | 18 Years - | Hoffmann-La Roche | |
| Rucaparib in Nonmetastatic prOstAte With BRCAness | NCT03533946 | Prostate Cancer | Rucaparib | 18 Years - | University of Utah | |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | NCT01891344 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Oral rucaparib | 18 Years - | pharmaand GmbH | |
| Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | NCT03572478 | Prostate Cancer Endometrial Can... | Rucaparib Nivolumab | 18 Years - | University of Chicago | |
| PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations | NCT01074970 | Breast Cancer | Cisplatin Rucaparib Cisplatin | 18 Years - | Hoosier Cancer Research Network | |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | NCT02855944 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Chemotherapy Rucaparib | 18 Years - | pharmaand GmbH | |
| A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib | NCT02873962 | Peritoneal Canc... Ovarian Cancer Fallopian Tube ... | Bevacizumab Nivolumab Rucaparib | 18 Years - | Dana-Farber Cancer Institute | |
| Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy | NCT03639935 | Biliary Tract C... | Rucaparib Nivolumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | NCT02855944 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Chemotherapy Rucaparib | 18 Years - | pharmaand GmbH | |
| Pharmacokinetic Drug-Drug Interaction Study of Rucaparib | NCT02740712 | Neoplasms | Caffeine Warfarin Omeprazole Midazolam digoxin Vitamin K Rucaparib | 18 Years - | pharmaand GmbH | |
| Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair | NCT03318445 | Solid Tumor, Un... | Rucaparib Irinotecan | 18 Years - | University of California, San Francisco | |
| A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer | NCT02935634 | Advanced Gastri... | Nivolumab Ipilimumab Relatlimab BMS-986205 Rucaparib | 18 Years - | Bristol-Myers Squibb | |
| Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor | NCT03521037 | Neoplasms | Rucaparib camsy... | 18 Years - | pharmaand GmbH | |
| A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma | NCT04624178 | Leiomyosarcoma | Rucaparib Nivolumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Rucaparib in Nonmetastatic prOstAte With BRCAness | NCT03533946 | Prostate Cancer | Rucaparib | 18 Years - | University of Utah | |
| Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium | NCT03476798 | Cervical Cancer Endometrial Can... | Rucaparib Bevacizumab | 18 Years - 99 Years | University of Oklahoma | |
| A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature | NCT02505048 | Metastatic Brea... | rucaparib | 18 Years - 99 Years | UNICANCER | |
| Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy | NCT03639935 | Biliary Tract C... | Rucaparib Nivolumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | NCT03824704 | Epithelial Ovar... Fallopian Tube ... Primary Periton... High Grade Sero... Endometrioid Ad... | Rucaparib Nivolumab | 18 Years - | pharmaand GmbH | |
| PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations | NCT01074970 | Breast Cancer | Cisplatin Rucaparib Cisplatin | 18 Years - | Hoosier Cancer Research Network | |
| Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial | NCT02678182 | Adenocarcinoma ... Adenocarcinoma ... Adenocarcinoma ... | Capecitabine MEDI4736 Trastuzumab Rucaparib Ramucirumab | 18 Years - | Royal Marsden NHS Foundation Trust |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
